Pharma 4.0 Market Size, Share & Trends Analysis Report By Type (Software, Services), By Technology (AI/ML, Big Data Analytics, IoT, Blockchain Technology), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030

Pharma 4.0 Market Size, Share & Trends Analysis Report By Type (Software, Services), By Technology (AI/ML, Big Data Analytics, IoT, Blockchain Technology), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030


Pharma 4.0 Market Growth & Trends

The global pharma 4.0 market size is expected to reach USD 35.79 billion by 2030, registering a CAGR of 18.96% from 2024 to 2030, according to a new report by Grand View Research, Inc. The pharma 4.0 market is being driven by several key factors, including the rising demand for personalized medicine, the need for improved efficiency and cost reduction, supply chain optimization, and an increasing focus on patient-centric approaches. The growing prevalence of chronic disorders and rare diseases has heightened the demand for personalized medicine. Pharma 4.0 technologies, such as additive manufacturing (3D printing) and modular production facilities, enable the production of personalized medicines and small batches tailored to individual patient needs, supporting this trend.

In addition, increasing adoption of digital technologies is driving the market growth. These technologies optimize, improve, and revolutionize drug development, manufacturing, distribution, and patient care. Blockchain technology has significantly reshaped supply chain management by offering transparency, traceability, and optimization, reducing stockouts, preventing counterfeiting, and enhancing overall efficiency and patient safety.

Furthermore, the market growth is being driven by increasing investments from pharmaceutical companies in adopting Pharma 4.0 technologies. For example, AstraZeneca signed a deal worth up to USD 840 million for the target identification of rare neurodegenerative and neuromuscular diseases. As part of this deal, AstraZeneca’s Alexion division will collaborate with Verge Genomics to identify drug targets for these conditions. Over the course of the four-year, multi-target agreement, the companies will utilize machine learning to analyze Verge’s genomic datasets, which are derived from human tissue rather than cell or animal models.

Pharma 4. 0 Market Report Highlights
  • On the basis of type, the software segment dominated the market in 2023, owing to the increasing adoption of software due to various benefits such as efficiency enhancement, improved compliance and productivity. In addition, the IoT enabled software help in real time monitoring and tracking of manufacturing process, leading to better process control and reduces the downtime
  • On the basis of technology, the AI & ML segment held the largest market share owing to growing adoption of AI and increasing investments. For instance, as per a survey, over 75% of pharma executives plan to apply AI to speed drug discovery by 2025
  • On the basis of application, the drug discovery & development dominated the market in 2023 due to increased investment in AI for drug discovery startups
  • Pharma & biotech segment held the largest market share of 49.8% in 2023. Pharmaceutical companies are increasingly adopting Pharma 4.0 technologies to enhance efficiency, productivity, and quality in their manufacturing processes thereby driving the segment growth
  • North America dominated the global market with a revenue share of 41.12% in 2023. The growth is attributed to the increasing government initiative, technological advancement in the healthcare industry, and a strong presence of key market players
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Type
1.1.2. Technology
1.1.3. Application
1.1.4. End Use
1.1.5. Regional scope
1.1.6. Estimates and forecast timeline.
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database.
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Approach 1: Commodity flow approach
1.6.3. Volume price analysis (Model 2)
1.6.4. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Pharma 4.0 Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Pharma 4.0 Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. COVID-19 Impact
Chapter 4. Pharma 4.0 Market: Type Estimates & Trend Analysis
4.1. Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Pharma 4.0 Market by Type Outlook
4.4. Software
4.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
4.5. Services
4.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
Chapter 5. Pharma 4.0 Market: Technology Estimates & Trend Analysis
5.1. Technology Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Pharma 4.0 Market by Technology Outlook
5.4. AI & ML
5.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
5.5. Big Data Analytics
5.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
5.6. IoT
5.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)
5.7. Block chain Technology
5.7.1. Market estimates and forecast 2018 to 2030 (USD Billion)
5.8. Others (Digital twin, Advanced robotics, AR &VR)
5.8.1. Market estimates and forecast 2018 to 2030 (USD Billion)
Chapter 6. Pharma 4.0 Market: Application Estimates & Trend Analysis
6.1. Application Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Pharma 4.0 Market by Application Outlook
6.4. Drug Discovery & Development
6.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
6.5. Manufacturing
6.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
6.6. Supply Chain Management
6.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)
6.7. Others (Product Lifecycle Management, Personalized Medicine, Regulatory Compliance)
6.7.1. Market estimates and forecast 2018 to 2030 (USD Billion)
Chapter 7. Pharma 4.0 Market: End Use Estimates & Trend Analysis
7.1. End Use Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Pharma 4.0 Market by End Use Outlook
7.4. Pharma & Biotech companies
7.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
7.5. Healthcare Providers
7.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
7.6. CRO & CDMO
7.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)
Chapter 8. Pharma 4.0 Market: Regional Estimates & Trend Analysis, By type, By technology, By Application, By End Use
8.1. Regional Market Share Analysis, 2023 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
8.5. North America
8.5.1. U.S.
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
8.5.2. Canada
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
8.5.3. Mexico
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
8.6. Europe
8.6.1. UK
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
8.6.2. Germany
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
8.6.3. France
8.6.3.1. Key country dynamics
8.6.3.2. Regulatory framework/ reimbursement structure
8.6.3.3. Competitive scenario
8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
8.6.4. Italy
8.6.4.1. Key country dynamics
8.6.4.2. Regulatory framework/ reimbursement structure
8.6.4.3. Competitive scenario
8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
8.6.5. Spain
8.6.5.1. Key country dynamics
8.6.5.2. Regulatory framework/ reimbursement structure
8.6.5.3. Competitive scenario
8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
8.6.6. Norway
8.6.6.1. Key country dynamics
8.6.6.2. Regulatory framework/ reimbursement structure
8.6.6.3. Competitive scenario
8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
8.6.7. Sweden
8.6.7.1. Key country dynamics
8.6.7.2. Regulatory framework/ reimbursement structure
8.6.7.3. Competitive scenario
8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
8.6.8. Denmark
8.6.8.1. Key country dynamics
8.6.8.2. Regulatory framework/ reimbursement structure
8.6.8.3. Competitive scenario
8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
8.7. Asia Pacific
8.7.1. Japan
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
8.7.2. China
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
8.7.3. India
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
8.7.4. Australia
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
8.7.5. South Korea
8.7.5.1. Key country dynamics
8.7.5.2. Regulatory framework/ reimbursement structure
8.7.5.3. Competitive scenario
8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
8.7.6. Thailand
8.7.6.1. Key country dynamics
8.7.6.2. Regulatory framework/ reimbursement structure
8.7.6.3. Competitive scenario
8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
8.8. Latin America
8.8.1. Brazil
8.8.1.1. Key country dynamics
8.8.1.2. Regulatory framework/ reimbursement structure
8.8.1.3. Competitive scenario
8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
8.8.2. Argentina
8.8.2.1. Key country dynamics
8.8.2.2. Regulatory framework/ reimbursement structure
8.8.2.3. Competitive scenario
8.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
8.9. MEA
8.9.1. South Africa
8.9.1.1. Key country dynamics
8.9.1.2. Regulatory framework/ reimbursement structure
8.9.1.3. Competitive scenario
8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
8.9.2. Saudi Arabia
8.9.2.1. Key country dynamics
8.9.2.2. Regulatory framework/ reimbursement structure
8.9.2.3. Competitive scenario
8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
8.9.3. UAE
8.9.3.1. Key country dynamics
8.9.3.2. Regulatory framework/ reimbursement structure
8.9.3.3. Competitive scenario
8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
8.9.4. Kuwait
8.9.4.1. Key country dynamics
8.9.4.2. Regulatory framework/ reimbursement structure
8.9.4.3. Competitive scenario
8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Key company market share analysis, 2023
9.4. Company Profiles
9.4.1. Microsoft Corporation
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. IBM
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. Amazon Web Service (AWS)
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. SAP
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Oracle
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. GE Healthcare
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Siemens Healthineers
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
9.4.8. Cisco
9.4.8.1. Company overview
9.4.8.2. Financial performance
9.4.8.3. Product benchmarking
9.4.8.4. Strategic initiatives
9.4.9. Cinntra
9.4.9.1. Company overview
9.4.9.2. Financial performance
9.4.9.3. Product benchmarking
9.4.9.4. Strategic initiatives
9.4.10. Dassault Systems
9.4.10.1. Company overview
9.4.10.2. Financial performance
9.4.10.3. Product benchmarking
9.4.10.4. Strategic initiatives
9.4.11. Nexocode
9.4.11.1. Company overview
9.4.11.2. Financial performance
9.4.11.3. Product benchmarking
9.4.11.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings